Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterising cause of death among people treated for drug-susceptible TB in India.
Cox SR, Padmapriyadarsini C, Mave V, Seth B, Thiruvengadam K, Gaikwad S, Sahasrabudhe TR, Sane M, Tornheim JA, Shrinivasa BM, Lokhande R, Barthwal MS, Shivakumar SVBY, Krishnan S, Santhappan R, Kinikar A, Kakrani AL, Paradkar M, Bollinger RC, Sekar K, Gupte AN, Hanna LE, Gupta A, Golub JE. Cox SR, et al. Among authors: mave v. Int J Tuberc Lung Dis. 2023 Jan 1;27(1):78-80. doi: 10.5588/ijtld.22.0454. Int J Tuberc Lung Dis. 2023. PMID: 36853129 No abstract available.
Management of intracranial tuberculous mass lesions: how long should we treat for?
Marais S, Van Toorn R, Chow FC, Manesh A, Siddiqi OK, Figaji A, Schoeman JF, Meintjes G; Tuberculous Meningitis International Research Consortium. Marais S, et al. Wellcome Open Res. 2019 Oct 31;4:158. doi: 10.12688/wellcomeopenres.15501.2. eCollection 2019. Wellcome Open Res. 2019. PMID: 32047859 Free PMC article.
Cytomegalovirus disease in African-American kidney transplant patients.
McGee J, Mave V, Yau CL, Killackey M, Paramesh A, Buell J, Slakey DP, Hamm LL, Zhang R. McGee J, et al. Among authors: mave v. Transpl Infect Dis. 2012 Dec;14(6):604-10. doi: 10.1111/j.1399-3062.2012.00759.x. Transpl Infect Dis. 2012. PMID: 23228184 Free PMC article.
West Nile virus in a kidney transplant recipient.
Stein RA, Zarifian A, Paramesh A, Mave V. Stein RA, et al. Among authors: mave v. Nephrol Nurs J. 2010 May-Jun;37(3):301-3. Nephrol Nurs J. 2010. PMID: 20629468 No abstract available.
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC; A5288 Team. Grinsztejn B, et al. Among authors: mave v. Lancet HIV. 2019 Sep;6(9):e588-e600. doi: 10.1016/S2352-3018(19)30146-8. Epub 2019 Jul 29. Lancet HIV. 2019. PMID: 31371262 Free PMC article. Clinical Trial.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B; A5288 Study team. Avihingsanon A, et al. Among authors: mave v. J Int AIDS Soc. 2022 Jun;25(6):e25905. doi: 10.1002/jia2.25905. J Int AIDS Soc. 2022. PMID: 36039892 Free PMC article.
170 results